Slayback Pharma announces approval and launch of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr®.
PRINCETON, N.J., Sept. 2, 2020 /PRNewswire/ -- Slayback Pharma, LLC announced today that it has received final approval for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled Syringe - a generic equivalent of Firazyr.
Ajay Singh, CEO of Slayback Pharma, said: "The approval of Icatibant, a difficult-to-characterize peptide, in a prefilled syringe injection, is yet another example of Slayback's track record on difficult generics. Our readiness to commence launch immediately upon approval despite the difficulties of the current Covid-19 global lockdown is a testimony to the commitment that our team and our partners have displayed to deliver essential medicines to patients against all odds."
See the following important safety information and refer to the package insert for full prescribing information.
Indication
Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Important Safety Information for Icatibant
Angioedema (which can include swelling of the throat or larynx) can be life-threatening. Inject Icatibant and go to the nearest hospital emergency room immediately if you have a laryngeal attack.
Do not take Icatibant if you are allergic to it or any other ingredient in the formulation.
Do not administer if the product contains visible particulate material or is discolored.
Do not take more than 3 doses in 24 hours.
Do not drive or use machinery if you feel dizzy, drowsy, or tired.
Use only the needle that is provided with the syringe.
Please discuss with your doctor if you:
are taking any blood pressure medications
have hepatic or renal disease
are pregnant, nursing, or planning on being pregnant or nursing
are under the age of 18
recently experienced a heart attack, unstable angina, or a stroke
have any other medical conditions
Some known side effects are:
redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site
dizziness
drowsiness
fever
headache
increase in transaminase (liver enzyme) levels
nausea
rash
tiredness
These are not all the possible side effects of Icatibant. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Tell your healthcare provider if you have any other medical conditions. You and your healthcare provider will decide if Icatibant is right for you.
For more information, please see full Prescribing Information.
You are encouraged to report any side effects or adverse event by calling 1-844-566-2505 or emailing [email protected]. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.
Slayback Pharma is a New Jersey-based pharmaceutical company focused on the development of complex and specialty generic products.
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference.
On April 26, 2024, the hearing will commence 11:15 a.m.
Members of the public may observe the hearing by videoconference, by...
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...